olmesartan medoxomil has been researched along with Alloxan Diabetes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, TX; Ding, A; Li, ZL; Yang, H; Zhang, H; Zhang, HT; Zhu, WP; Zhu, Y | 1 |
| Arakawa, N; Domon, Y; Inoue, T; Nakamura, H; Yokoyama, T | 1 |
| Giridharan, VV; Kodama, M; Lakshmanan, AP; Meilei, H; Palaniyandi, SS; Sari, FR; Soetikno, V; Suzuki, K; Thandavarayan, RA; Watanabe, K | 1 |
| Nandi, U; Pal, TK; Sengupta, P | 1 |
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Harada, N; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S | 1 |
6 other study(ies) available for olmesartan medoxomil and Alloxan Diabetes
| Article | Year |
|---|---|
Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Male; Mice; Olmesartan Medoxomil | 2019 |
Olmesartan medoxomil ameliorates sciatic nerve regeneration in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Ciliary Neurotrophic Factor; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Ganglia, Spinal; Gene Expression Regulation; Imidazoles; Insulin-Like Growth Factor I; Male; Nerve Regeneration; Neurotrophin 3; Olmesartan Medoxomil; Rats; Rats, Sprague-Dawley; Receptor, Ciliary Neurotrophic Factor; RNA, Messenger; Sciatic Neuropathy; Streptozocin; Tetrazoles | 2009 |
Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Glucose; Caspase 12; Diabetes Mellitus, Experimental; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Imidazoles; JNK Mitogen-Activated Protein Kinases; Kidney; Lipid Peroxidation; Malondialdehyde; Membrane Proteins; Mice; Olmesartan Medoxomil; Protein Serine-Threonine Kinases; Receptor, Angiotensin, Type 1; Superoxides; Tetrazoles; TNF Receptor-Associated Factor 2; Transcription Factor CHOP | 2011 |
Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Area Under Curve; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Female; Hypoglycemic Agents; Imidazoles; Male; Olmesartan Medoxomil; Pioglitazone; Rats; Rats, Wistar; Tetrazoles; Thiazolidinediones | 2012 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Cilnidipine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous NIDDM.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Tolerance Test; Imidazoles; Insulin; Insulin Resistance; Lipid Metabolism; Male; Olmesartan Medoxomil; Rats; Rats, Inbred OLETF; Tetrazoles; Time Factors | 1999 |